Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875754 | 0.93 | RAD52 (0.42) | RAD52HTR2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5875888 | 0.84 | RAD52 (0.40) | RAD52HTR2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5875809 | 0.83 | MAPT (0.36) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL5875893 | 0.78 | RAD52 (0.44) | RAD52HTR2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL238449 | 0.77 | HTR2C (0.41) | RAD52HTR2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5875749 | 0.76 | MAPT (0.36) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL240763 | 0.72 | KMT2A (0.42) | RAD52KMT2AMEN1SMN1; SMN2POLB | |
| SCHEMBL13163275 | 0.71 | HTR2C (0.41) | RAD52HTR2CKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL239478 | 0.68 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2POLBMAPT | |
| SCHEMBL4986665 | 0.67 | GABRA1 (0.40) | RAD52KMT2AMEN1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989387-B2 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-06-10 | — | — | US | disclosed |
| WO-2004014918-A1 | NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | RAD52 676/4885HTR2C 3821/4885KMT2A 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.